Your browser doesn't support javascript.
loading
SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up.
Salehi-Vaziri, Mostafa; Pouriayevali, Mohammad Hassan; Fotouhi, Fatemeh; Jalali, Tahmineh; Banifazl, Mohammad; Farahmand, Behrokh; Sadat Larijani, Mona; Ahmadi, Zahra; Fereydouni, Zahra; Tavakoli, Mahsa; Karami, Afsaneh; Azad-Manjiri, Sanam; Yektay Sanati, Parastoo; Dahmardeh, Sarah; Nemati, Amir Hesam; Sajadi, Marzyie; Kashanian, Setareh; Ramezani, Amitis.
  • Salehi-Vaziri M; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: mostafvaziri1985@gmail.com.
  • Pouriayevali MH; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: m.h.pouria@gmail.com.
  • Fotouhi F; Department of Influenza and Other Respiratory Viruses of Pasteur Institute of Iran, Tehran, Iran. Electronic address: fotouhi44@yahoo.com.
  • Jalali T; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: jalalitahmineh@gmail.com.
  • Banifazl M; Iranian Society for Support of Patients with Infectious Disease, Tehran, Iran. Electronic address: mohammad.banifazl@aol.com.
  • Farahmand B; Department of Influenza and Other Respiratory Viruses of Pasteur Institute of Iran, Tehran, Iran. Electronic address: b_farahmand@pasteur.ac.ir.
  • Sadat Larijani M; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran. Electronic address: mona.sadat@gmail.com.
  • Ahmadi Z; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: zahraahmadii1995@gmail.com.
  • Fereydouni Z; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: zahrafereydouni70@gmail.com.
  • Tavakoli M; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: mahsa.tavakolirad@gmail.com.
  • Karami A; Department of Infectious Disease, Zanjan University of Medical Sciences, Zanjan, Iran. Electronic address: dr.akarami@yahoo.com.
  • Azad-Manjiri S; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: s.a_92@yahoo.com.
  • Yektay Sanati P; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran. Electronic address: p.yekta.oloom@gmail.com.
  • Dahmardeh S; Vaccination Department, Pasteur Institute of Iran, Tehran, Iran. Electronic address: sarahdahmardeh@gmail.com.
  • Nemati AH; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran. Electronic address: hesam.nemati@live.com.
  • Sajadi M; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran. Electronic address: marziiie.97@gmail.com.
  • Kashanian S; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran. Electronic address: setareh.kashanian76@gmail.com.
  • Ramezani A; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran. Electronic address: amitisramezani@hotmail.com.
Microb Pathog ; 161(Pt B): 105296, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34801646
ABSTRACT
Since the COVID-19 pandemic initiation, the possibility of re-infection has been unclearly present. Although herd immunity has a potential reliance through natural infection, human corona viruses has the ability to subvert immunity and re-infection happens for seasonal corona viruses. Currently, the frequency of SARS-CoV-2 re-infection incidence is not exactly defined. In this study we aimed at determination of SARS-CoV-2 re-infection rate in Iranian population. In a total of 5696 COVID-19 suspicious individuals, RT-PCR was applied to diagnose the infection. The confirmed patients were followed for 12 months and serology tests were applied to measure the specific antibodies. Among 1492 confirmed COVID-19 cases, five individuals experienced the subsequent infection. The re-infection/reactivation incidence rate was totally 0.33% after one year of follow-up. The interval ranged from 63 to 156 days. All the cases had viral mutations in the second episode of the infection. All of them were symptomatic cases with moderate severity. The estimated rate of SARS-CoV-2 in Persian population is therefore rare and natural infection seems to induce good protection against re-infection which clarifies that mass vaccination can hugely affect the society.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans País como asunto: Asia Idioma: En Año: 2021 Tipo del documento: Article